SPY345.78+1.17 0.34%
DIA283.34-0.31 -0.11%
IXIC11,548.28+42.28 0.37%

Actinium Pharmaceuticals Announces The Launch Of New Research & Development Lab Facility In New York

Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City.  This new research

· 10/14/2020 07:06

Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City.  This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development.  The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225.  

(PRNewsfoto/Actinium Pharmaceuticals, Inc.)

This new research facility will function under the guidance of Dr. Dale Ludwig, Ph.D. the Company's Chief Scientific & Technology Officer, who has over twenty-five years of oncology discovery research and development experience, including supporting the development and launch of Erbitux®, CyramzaTM, Portrazza®, and LartruvoTM as well as the clinical advancement of at least 10 additional therapeutic antibodies and Antibody Drug Conjugates while at Eli Lilly and, previously, ImClone Systems Inc.  The research facility will be managed and staffed by Ph.D. level scientists who will contribute their respective expertise in areas of drug discovery, radiation chemistry, and translational research to advance novel ARC programs and investigations into combination therapeutic strategies.

"Our new research facility will allow us to significantly accelerate our preclinical and clinical development of novel ARC programs and investigate mechanistic ARC therapeutic combinations, which utilize our expertise in radioimmunobiology, our AWE Technology Platform capabilities, and know-how," said Dale Ludwig.  "The establishment of an internal research facility was a priority for Actinium's long-term strategy, as we look to deliver on our pipeline development activities, as well as expand our portfolio of promising product candidates through partnerships and collaborations.  Furthermore, in both preclinical and clinical studies, we have shown mechanistic synergies when our ARCs are combined with novel and approved therapeutic agents in treating cancer.  The addition of this R&D facility will enable more rapid investigation of novel mechanistic drug combinations that can be effectively translated into clinical testing."

Over the last eighteen months, Actinium has advanced its research and discovery activities in three key areas —the development of next generation ARCs, therapeutic combinations with ARCs, and improved targeted conditioning treatments for adoptive cell therapies such as CAR-T.  As presented at the 2018 AACR Annual Meeting, cell death improved as much as thirty-fold and cell death occurred in treatment resistant cell lines when daratumumab, an anti-CD38 directed antibody approved for the treatment of multiple myeloma (MM), was labeled with Ac-225 using Actinium's AWE Technology Platform.  The power and potency of Actinium's AWE Technology Platform is also demonstrated in an ongoing Actimab-A combination study with CLAG-M in difficult to treat R/R AML patients. Patients treated with a sub-therapeutic dose of Actimab-A combined with CLAG-M had improved response rates by over 60% versus CLAG-M treatment alone.  In September, preclinical data supporting Iomab-ACT as a viable and effective method for achieving targeted lymphodepletion prior to an adoptive cell therapy such as CAR-T was published in the journal Oncotarget (https://www.oncotarget.com/archive/v11/i39/).  Leveraging the new laboratory facility, Actinium intends to further its research activities in these areas which will aid in developing next generation targeted conditioning agents and exploring therapeutic combinations with ARCs and of proven oncology and immunooncology agents.

The Company intends to focus on generating novel ARCs, building on its existing intellectual property, evaluating assets for in-licensing to complement existing clinical pipeline, as well as securing collaborations and partnerships with other biopharmaceutical companies.  By adding research and development capabilities to its clinical development and clinical supply chain capabilities, Actinium will be positioned to enable the rapid translation of radioimmunotherapies into the clinic.  The Company's AWE platform intellectual property covers various methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations.  Actinium's AWE technology patent portfolio includes 29 patent families comprised of over 130 issued or pending global patent applications, of which 10 are issued and 31 pending in the United States.

Sandesh Seth, Chairman and Chief Executive Officer of Actinium, said, "The opening of our R&D facility is an important milestone that will support both internal and collaborative efforts at advancing the field of ARCs.  Our growing and highly talented R&D team is focused on harnessing the power of our AWE Technology Platform to enhance our clinical pipeline and drive current and additional collaborations.  Having these capabilities in house will allow us to more efficiently execute on our multi-disciplinary research efforts and continue to innovate and extend our leadership position in the growing field of ARCs."